


Registered number  
05848896

AMENDED

Alissa Healthcare Research Limited

Unaudited Filleted Accounts

30 November 2020



**Alissa Healthcare Research Limited**  
**Registered number: 05848896**  
**Director's Report**

---

The director presents his report and accounts for the year ended 30 November 2020.

During 2020 two significant events impacted the overall performance of the company. Our major partner in India lost their GMP status. This has resulted in a reduction of sales amounting to circa £1.45m. Had the partner maintained seamless supply throughout 2019 and 2020, with organic growth and pipeline anticipated sales from this source would have exceeded £3m.

The Company accepted the Competition and Marketing Authority's decision in respect of information sharing and duly paid a fine of £174,912. Subsequently the Company successfully appealed against director disqualification and in consequence the underlying core business activity has effectively continued without interruption.

Mr. Bill Ray has been appointed as Non-executive director.

R&D investment has continued unhindered. The company is likely to see the benefits of this long-term commitment during the financial year 2021-2022.

**Principal activities**

The company's principal activity during the year continued to be buying and selling pharmaceutical products.

**Directors**

The following persons served as directors during the year:

R. Davies

**Small company provisions**

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

This report was approved by the board on 20 October 2021 and signed on its behalf.

A handwritten signature in black ink, appearing to read 'R. Davies', followed by a horizontal line extending to the right.

R. Davies  
Director

**Alissa Healthcare Research Limited**  
**Registered number:** 05848896  
**Balance Sheet**  
**as at 30 November 2020**

	Notes	2020 £	2019 £
<b>Fixed assets</b>			
Tangible assets	3	56,050	73,854
<b>Current assets</b>			
Stocks		2,143,434	1,269,806
Debtors	4	4,819,361	4,648,984
Cash at bank and in hand		1,299,465	2,458,204
		<u>8,262,260</u>	<u>8,376,994</u>
<b>Creditors: amounts falling due within one year</b>	5	(616,887)	(663,967)
<b>Net current assets</b>		<u>7,645,373</u>	<u>7,713,027</u>
<b>Total assets less current liabilities</b>		<u>7,701,423</u>	<u>7,786,881</u>
<b>Provisions for liabilities</b>		(2,930)	(5,820)
<b>Net assets</b>		<u>7,698,493</u>	<u>7,781,061</u>
<b>Capital and reserves</b>			
Called up share capital		108,100	108,100
Profit and loss account		7,590,393	7,672,961
<b>Shareholders' funds</b>		<u>7,698,493</u>	<u>7,781,061</u>

The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.



R. Davies  
Director

Approved by the board on 20 October 2021

**Alissa Healthcare Research Limited**  
**Notes to the Accounts**  
**for the year ended 30 November 2020**

---

**1 Accounting policies**

***Basis of preparation***

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

***Turnover***

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

***Tangible fixed assets***

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

Plant and machinery	25% reducing balance
Motor vehicles	25% reducing balance

***Investments***

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

***Stocks***

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in first out method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.

***Debtors***

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

***Creditors***

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

**Alissa Healthcare Research Limited**  
**Notes to the Accounts**  
**for the year ended 30 November 2020**

---

***Taxation***

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

***Provisions***

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

**2 Employees**

	<b>2020 Number</b>	<b>2019 Number</b>
Average number of persons employed by the company	<u>10</u>	<u>9</u>

**3 Tangible fixed assets**

	<b>Plant and machinery etc £</b>	<b>Motor vehicles £</b>	<b>Total £</b>
<b>Cost</b>			
At 1 December 2019	215,603	22,600	238,203
Additions	881	-	881
At 30 November 2020	<u>216,484</u>	<u>22,600</u>	<u>239,084</u>
<b>Depreciation</b>			
At 1 December 2019	151,283	13,066	164,349
Charge for the year	16,301	2,384	18,685
At 30 November 2020	<u>167,584</u>	<u>15,450</u>	<u>183,034</u>
<b>Net book value</b>			
At 30 November 2020	<u>48,900</u>	<u>7,150</u>	<u>56,050</u>
At 30 November 2019	<u>64,320</u>	<u>9,534</u>	<u>73,854</u>

**Alissa Healthcare Research Limited**  
**Notes to the Accounts**  
**for the year ended 30 November 2020**

<b>4 Debtors</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Trade debtors	1,124,915	1,731,950
Other debtors	3,694,446	2,917,034
	<u>4,819,361</u>	<u>4,648,984</u>

<b>5 Creditors: amounts falling due within one year</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Trade creditors	303,958	241,342
Taxation and social security costs	261,937	277,133
Other creditors	50,992	145,492
	<u>616,887</u>	<u>663,967</u>

**6 Parent company**

The parent company of Alissa Healthcare Research Limited is Alissa Healthcare Holdings Ltd and its registered office is Unit 5 Fulcrum 1 Solent Way, Whiteley, Fareham, United Kingdom, PO15 7FE.

**7 Related party transactions and balances**

At the year end, £681,762 (2019: £981,762) was due from Alissa Healthcare Holdings Limited and is included within other debtors.

<b>Transactions with directors</b>	<b>At 1 December 2019 £</b>	<b>Advances to directors £</b>	<b>Repayments by directors £</b>	<b>At 30 November 2020 £</b>
<b>2020</b>				
<b>Mr R. Davies</b>				
Overdrawn directors loan included within other debtors	<u>1,911,712</u>	<u>1,077,412</u>	<u>-</u>	<u>2,989,124</u>

<b>Transactions with directors</b>	<b>At 1 December 2018 £</b>	<b>Advances to directors £</b>	<b>Repayments by directors £</b>	<b>At 30 November 2019 £</b>
<b>2019</b>				
<b>Mr R. Davies</b>				
Overdrawn directors loan included within other debtors	<u>-</u>	<u>1,911,712</u>	<u>-</u>	<u>1,911,712</u>

**Alissa Healthcare Research Limited**  
**Notes to the Accounts**  
**for the year ended 30 November 2020**

---

**8 Other information**

Alissa Healthcare Research Limited is a private company limited by shares and incorporated in England. Its registered office is:

Unit 5 Fulcrum 1

Solent Way

Whiteley

Fareham

PO15 7FE